美国前列腺特异性抗原检测共享决策的患病率及其决定因素
该研究基于2019年美国国家健康访谈调查,评估40岁及以上无前列腺癌病史男性中前列腺特异性抗原(PSA)检测的共享决策(SDM)情况。在9723名参与者中,仅24.1%报告与医生进行过SDM,62.9%从未讨论过PSA检测;年轻和低教育水平是SDM参与减少的主要决定因素。
要点
- 在9723名40岁及以上无前列腺癌病史男性中,仅24.1%报告与医生进行过PSA检测的共享决策。
- 62.9%的男性从未与医生讨论过PSA检测,终生PSA检测率为45.9%,1年检测率为29.1%。
- 年轻和低教育水平是共享决策参与减少的主要决定因素,低教育水平男性在所有年龄组中SDM参与率不到高教育水平者的一半。
核心结论
- 尽管社会指南推荐PSA检测采用共享决策,但大多数男性(无论年龄)从未与医疗保健提供者进行过关于PSA检测的SDM对话,尤其是教育水平较低者。
- 需要更多努力改善患者与提供者之间关于PSA检测潜在获益和危害的对话。
研究设计与样本
- 基于人群的研究,使用2019年美国国家健康访谈调查数据,纳入40岁及以上无前列腺癌病史的男性,评估PSA检测率和SDM参与情况。
- SDM定义为与医生讨论PSA检测的优点和缺点,使用多变量逻辑回归和机器学习识别与缺乏SDM相关的因素。
主要发现
- 在9723名符合条件的参与者(平均年龄58岁)中,终生PSA检测率为45.9%,1年检测率为29.1%。
- 仅24.1%报告与医生进行过SDM,而62.9%从未讨论过PSA检测。
- 年轻和较低教育水平是SDM参与减少的主要决定因素。
- 在所有年龄组中,教育水平较低的男性进行SDM的频率不到教育水平较高者的一半。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Shared decision-making (SDM) is recommended for prostate-specific antigen (PSA) testing but appears underutilized. This population-based study assessed the prevalence and determinants of SDM for PSA testing among US men. METHODS: We assessed PSA testing rates and SDM engagement in men aged 40 and older without prostate cancer history using the 2019 National Health Interview Survey. SDM was defined as discussing the advantages and disadvantages of PSA testing with a physician. We used multivariable logistic regression with machine learning to identify factors associated with lack of SDM. RESULTS: Among 9723 eligible participants (mean age 58 years), lifetime PSA testing prevalence was 45.9% and the 1-year testing incidence was 29.1%. Only 24.1% reported engaging in SDM with a physician, while 62.9% never discussed PSA testing. Younger age and lower education levels were the primary determinants of decreased SDM engagement. Men with less education engaged in SDM less than half as often as those with higher education levels across all age groups. CONCLUSIONS: Societal guidelines recommend SDM for PSA testing. However, most men, regardless of age, have never engaged in SDM conversations with a healthcare provider about PSA testing, especially those with less education. More efforts are needed to improve patient-provider conversations about the potential benefits and harms of PSA testing.
引用
- Bhojani N, Miller LE, Zorn KC, et al. Prevalence and determinants of shared decision-making for PSA testing in the United States. Prostate Cancer Prostatic Dis. 2024. PMID: 38671083. doi:10.1038/s41391-024-00843-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。